Book contents
- Respiratory Disease in Pregnancy
- Respiratory Disease in Pregnancy
- Copyright page
- Contents
- Contributors
- Section 1 The Basics: for the Obstetrician
- Section 2 The Basics: for the Non-Obstetrician
- Section 3 Pulmonary Conditions Not Specific to Pregnancy
- Section 4 Pulmonary Conditions Related to Pregnancy
- Section 5 Other Pulmonary Issues in Pregnancy
- 19 Tobacco Smoking in Pregnancy
- 20 Radiological Imaging of the Chest in Pregnancy
- 21 Respiratory Drug Therapy in Pregnancy
- 22 Biological and Immunosuppressive Respiratory Therapy in Pregnancy
- 23 Oxygen Therapy during Pregnancy
- 24 Airway Management in Pregnancy
- 25 Mechanical Ventilation in Pregnancy
- Index
- References
21 - Respiratory Drug Therapy in Pregnancy
from Section 5 - Other Pulmonary Issues in Pregnancy
Published online by Cambridge University Press: 14 April 2020
By
Book contents
- Respiratory Disease in Pregnancy
- Respiratory Disease in Pregnancy
- Copyright page
- Contents
- Contributors
- Section 1 The Basics: for the Obstetrician
- Section 2 The Basics: for the Non-Obstetrician
- Section 3 Pulmonary Conditions Not Specific to Pregnancy
- Section 4 Pulmonary Conditions Related to Pregnancy
- Section 5 Other Pulmonary Issues in Pregnancy
- 19 Tobacco Smoking in Pregnancy
- 20 Radiological Imaging of the Chest in Pregnancy
- 21 Respiratory Drug Therapy in Pregnancy
- 22 Biological and Immunosuppressive Respiratory Therapy in Pregnancy
- 23 Oxygen Therapy during Pregnancy
- 24 Airway Management in Pregnancy
- 25 Mechanical Ventilation in Pregnancy
- Index
- References
Summary
Prescribing in pregnancy and breastfeeding requires a thoughtful approach, considering maternal, fetal and neonatal physiology, and the pharmacokinetics of the prescribed drug. This chapter aims to familiarize the reader with pregnancy-related issues that should be taken into account when prescribing medications in the peri-partum period.
- Type
- Chapter
- Information
- Respiratory Disease in Pregnancy , pp. 195 - 199Publisher: Cambridge University PressPrint publication year: 2020
References
Anderson, GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet. 2005 44:989–1008.Google Scholar
Costantine, MM. Physiologic and pharmacokinetic changes in pregnancy. Front Pharmacol. 2014 5:65.Google Scholar
Frederiksen, MC. Physiologic changes in pregnancy and their effect on drug disposition. Semin Perinatol. 2001 25:120.CrossRefGoogle ScholarPubMed
Murphy, MM, Scott, JM, McParlin, JM, Fernandez-Ballart, JD. The pregnancy related decrease in fasting plasma homocysteine is not explained by folic acid supplementation, hemodilution, or a decrease in albumin in a longitudinal study. Am J Clin Nutr. 2002 76:614–19.Google Scholar
Brazier, JL, Ritter, J, Berland, M, Khenfer, D, Faucon, G. Pharmacokinetics of caffeine during and after pregnancy. Dev Pharmacol Ther. 1983 6(5):315–22.CrossRefGoogle Scholar
Tsutsumi, K, Kotegawa, T, Matsuki, S, et al. The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activities in humans. Clin Pharmacol Ther. 2001 70(2):121–5.Google Scholar
Grosso, LM, Bracken, MB. Caffeine metabolism, genetics, and perinatal outcomes: a review of exposure assessment considerations during pregnancy. Ann Epidemiol. 2005 15(6):460–6.CrossRefGoogle ScholarPubMed
Pennell, PB, Newport, DJ, Stowe, ZN, et al. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology. 2004 62(2):292–5.Google Scholar
Allegaert, K, van Mieghem, T, Verbesselt, R, et al. Cefazolin pharmacokinetics in maternal plasma and amniotic fluid during pregnancy. Am J Obstet Gynecol. 2009 200(2):170.e171–7.CrossRefGoogle ScholarPubMed
Muller, AE, Mouton, JW, Oostvogel, PM, et al. Pharmacokinetics of clindamycin in pregnant women in the peripartum period. Antimicrob Agents Chemother. 2010 54(5):2175–81.CrossRefGoogle ScholarPubMed
Tasnif, Y, Morado, J, Hebert, MF. Pregnancy-related pharmacokinetic changes. Clin Pharmacol Ther. 2016 100(1):53–62.Google Scholar
Pernia, S, DeMaagd, G. The new pregnancy and lactation labeling rule. P T. 2016 41(11): 713–15.Google ScholarPubMed
Sachs, HC; Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. Pediatrics 2013 132:e796.Google Scholar
Spencer, JP, Gonzalez, LS 3rd, Barnhart, DJ. Medications in the breast-feeding mother. Am Fam Physician. 2001 64:119.Google Scholar
Etwel, F, Faught, LH, Rieder, MJ, Koren, G. The risk of adverse pregnancy outcome after first trimester exposure to H1 antihistamines: a systematic review and meta-analysis. Drug Saf. 2017 40(2):121–32.Google Scholar
Aljazaf, K, Hale, TW, Ilett, KF, et al. Pseudoephedrine: effects on milk production in women and estimation of infant exposure via breastmilk. Br J Clin Pharmacol. 2003 56:18–24.Google Scholar
Torfs, CP, Katz, EA, Bateson, TF, et al. Maternal medications and environmental exposures as risk factors for gastroschisis. Teratology. 1996 54:84–92.3.0.CO;2-4>CrossRefGoogle ScholarPubMed
Werler, MM, Sheehan, JE, Hayes, C, et al. Vasoactive exposures, vascular events, and hemifacial microscomia. Birth Defects Res (Part A). 2004 70:389–95.CrossRefGoogle Scholar
World Health Organization. Guidelines for Treatment of Tuberculosis, 4th edn. Geneva: WHO. 2010. https://apps.who.int/iris/bitstream/handle/10665/255052/9789241550000-eng.pdf (accessed November 2019).Google Scholar